ATAI Overview

AtaiBeckley Inc. is a clinical-stage biotechnology company focused on transforming patient outcomes by developing rapid-acting and convenient mental health treatments. The Company's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is being developed to produce rapid treatment effects from a single dose, within a two-hour interventional psychiatry treatment paradigm, and with a favorable safety profile. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with treatment-resistant depression (TRD). EMP-01 is an oral formulation of R-MDMA.

Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is13.00 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AtaiBeckley Inc revenue for the last quarter amounts to 749.00K USD, increased 1772.50

AtaiBeckley Inc. EPS for the last quarter amounts to -0.28 USD, increased 75.00

AtaiBeckley Inc (ATAI) has 54 emplpoyees as of March 02 2026.

Today ATAI has the market capitalization of 1.34B USD.